What it is
Eloralintide (LY3841136) is an investigational selective amylin receptor agonist studied for obesity.
Evidence boundary
Human trial evidence exists, but eloralintide is still investigational and has no FDA-approved product label. The schedule below reflects published trial arms, not commercial prescribing guidance.
Trial evidence
- PMID 41109426 — Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.
- PMID 41559929 — Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.
- PMID 41207310 — Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.
protocol overview
Eloralintide has been studied as a once-weekly subcutaneous injection. The published trials are easier to scan in table form:
| Phase | Study design | Doses tested | Schedule | Key readout |
|---|---|---|---|---|
| Phase 1 | Healthy participants; randomized, placebo-controlled, participant- and investigator-blinded, multiple ascending-dose study | 0.04 mg to 12 mg | Once weekly SC | PK supported weekly dosing; week-4 weight change was dose-dependent |
| Phase 2 | 48-week obesity trial; multicentre, double-blind, randomized, placebo-controlled | Fixed: 1 mg, 3 mg, 6 mg, 9 mg. Escalation: 3 → 9 mg and 6 → 9 mg. | Once weekly SC on a consistent day | Mean weight loss ranged from about 9% at 1 mg to about 20% at 9 mg |
Phase 1
- Study design
- Healthy participants; randomized, placebo-controlled, participant- and investigator-blinded, multiple ascending-dose study
- Doses tested
- 0.04 mg to 12 mg
- Schedule
- Once weekly SC
- Key readout
- PK supported weekly dosing; week-4 weight change was dose-dependent
Phase 2
- Study design
- 48-week obesity trial; multicentre, double-blind, randomized, placebo-controlled
- Doses tested
- Fixed: 1 mg, 3 mg, 6 mg, 9 mg. Escalation: 3 → 9 mg and 6 → 9 mg.
- Schedule
- Once weekly SC on a consistent day
- Key readout
- Mean weight loss ranged from about 9% at 1 mg to about 20% at 9 mg
Phase 1 takeaways
- Doses ranged from 0.04 mg to 12 mg.
- Pharmacokinetics supported once-weekly dosing.
- Higher-dose cohorts produced the largest week-4 weight change signal.
Phase 2 takeaways
- 48-week obesity trial with fixed-dose and escalation arms.
- Fixed-dose arms: 1 mg, 3 mg, 6 mg, and 9 mg once weekly.
- Escalation arms: 3 → 9 mg and 6 → 9 mg stepwise escalation.
- Dosing stayed on a consistent weekly day.
- Mean weight loss ranged from about 9% at 1 mg to about 20% at 9 mg.
Phase 2 escalation arms
| Arm | Dosing pattern | Schedule | Note |
|---|---|---|---|
| 3 → 9 mg | Stepwise escalation to 9 mg | Once weekly SC | Investigational escalation arm |
| 6 → 9 mg | Stepwise escalation to 9 mg | Once weekly SC | Investigational escalation arm |
3 → 9 mg
- Dosing pattern
- Stepwise escalation to 9 mg
- Schedule
- Once weekly SC
- Note
- Investigational escalation arm
6 → 9 mg
- Dosing pattern
- Stepwise escalation to 9 mg
- Schedule
- Once weekly SC
- Note
- Investigational escalation arm
Dosing and titration rationale
Eloralintide appears to have a selective amylin-receptor profile. The trial data support gradual escalation when tolerability is a concern:
- lower-step escalation can reduce nausea and fatigue
- fixed-dose arms still produced meaningful weight loss
- the 9 mg arm delivered the strongest efficacy signal in the published phase 2 data
Combination context
Eloralintide is being explored in combination research with tirzepatide. That combination remains investigational.
What to monitor
- Appetite suppression and early satiety
- Nausea
- Fatigue
- Vomiting
- Body-weight response over time
- Overall gastrointestinal tolerability
Practical rules
- Keep the dosing day consistent week to week.
- Smaller meals are usually easier to tolerate when amylin signaling is strong.
- Watch for dose-dependent GI effects during escalation.
- Treat published trial arms as research context, not a retail dosing template.
- If the goal is comparison research, line eloralintide up against cagrilintide, retatrutide, and tirzepatide rather than treating it like a standard approved obesity label.